Corticosteroid Lumbar Epidural Analgesia for Radiculopathy

• Status: Active, not recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a research study of SP-102, an experimental medication designed to relieve pain in patients with a specific type of leg pain. The mediation is given once by your healthcare professional, with a possibility of a second injection as early as about 1 month after the first treatment.

The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain. The study will also investigate the side effects of SP-102.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Scilex Pharmaceuticals, Inc.
• Collaborators: Semnur Pharmaceuticals, Inc.; Worldwide Clinical Trials

Criteria

Main Inclusion Criteria:

• Able and willing to read, write, and understand the English language and provide English language written informed consent prior to beginning any study procedures.

• Age 18 to 70 years (inclusive) at the Screening Visit.

• A diagnosis of lumbosacral radicular pain (sciatica).

• Agrees to follow study-specific medication requirements.

• If sexually active and a female of child-bearing potential or a male capable of bearing a child, agrees to use an effective method of birth control during the study.

• Has reviewed all study specific materials and has, in the opinion of the Investigator, the abilities to understand and appropriately complete all study procedures.

Main Exclusion Criteria:

• Has radiologic evidence of a condition that would compromise study outcomes.

• Has ever had lumbosacral back surgery or plans to undergo spine surgical intervention while in the study.

• Has been diagnosed with insulin dependent diabetes mellitus.

• Presence of any other disorder, condition or circumstance (including secondary gain) that, in the opinion of the Investigator, has the potential to prevent study completion and/or to have a confounding effect on outcome assessments.

• Use of any investigational drug and/or device within 30 days, or is scheduled to receive an investigational drug other than blinded study drug during this study.

• Has a body mass index ≥40 kg/m2.